What is orforglipron?

Orforglipron (sold as Foundayo) is the first FDA-approved daily oral non-peptide GLP-1 — no fasting window required, unlike Rybelsus.

Orforglipron (sold as Foundayo) is the first FDA-approved daily oral non-peptide GLP-1 — no fasting window required, unlike Rybelsus. Made by Eli Lilly, orforglipron is a small-molecule GLP-1 receptor agonist. Because it's not a peptide, it survives the stomach without needing the absorption-enhancer Rybelsus depends on — so it can be taken any time of day, with or without food. Approved by the FDA in April 2026 for weight management in adults, it starts at 0.8 mg once daily and steps up at least 30 days apart, to as much as 17.2 mg. At 17.2 mg, average weight loss was 11.1% at 72 weeks in the main trial (FDA label), a little less than injectable semaglutide or tirzepatide. Foundayo is positioned as the easier on-ramp for people who don't want weekly injections — same GLP-1 mechanism, oral once-daily dosing, no fasting window.

Related pages

• Foundayo tracker
• Foundayo vs injectable GLP-1s
• GLP-1 glossary

Get the GLPeak app

Download GLPeak on the App Store · Get GLPeak on Google Play